linjc16/ctgov huggingface dataset:
Dual Trigger Versus Booster Dose of HCG

Study Overview
=================
Brief Summary
-----------------
To salvage the luteal phase and improve pregnancy rate in antagonist IVF/ICSI cycles triggered with GnRH agonist. Two strategies are compared dual trigger with GnRH agonist plus 1000 IU of HCG or triggering with GnRH and giving a booster dose of HCG (1500 IU) on the day of ovum pickup.

Official Title
-----------------
Dual Trigger Versus Booster Dose of HCG on Ovum Pickup Day in Antagonist IVF/ICSI Cycles Triggered With GnRH Agonist in High Responder Females to Salvage the Luteal Phase

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Procedure: IVF/ICSI
* Drug: Human Chorionic Gonadotropin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: High responder females undergoing antagonist protocol IVF/ICSI cycle More than 14 MII oocytes Estradiol more than 3500 pg/ml on day of trigger Exclusion Criteria: Any other protocol Normal or poor responders

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 37 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Dual trigger<br>GnRH agonist plus 1000 IU of HCG to trigger final maturation | Procedure: IVF/ICSI<br> <br> Drug: Human Chorionic Gonadotropin<br>* given in different doses and timing to support the luteal phase<br>|
| Active Comparator: Booster HCG dose<br>GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup | Procedure: IVF/ICSI<br> <br> Drug: Human Chorionic Gonadotropin<br>* given in different doses and timing to support the luteal phase<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate | The number of cycles with a evidence of a gestational sac with fetal pulstaions after 5 weeks from pregnancy test | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OHSS rate | The number of cycles with evidence of OHSS | 1 year |
Prospective Study to Observe and Manage Progression of Pulmonary Nodules

Study Overview
=================
Brief Summary
-----------------
Based on the previous review and research, we would like to further observe the nodule changes in patients with pulmonary nodules. These changes include factors such as the reason for the further enlargement or deterioration of the nodule, time, lifestyle, the patient's region, and hereditary medical history. At the same time, we will further look at the corresponding characteristics of a population that does not change the size and nature of the nodule, including age, gender, and all the factors discussed above. On this basis, we can propose more scientific methods for the treatment and management of pulmonary nodules, and provide a more reliable clinical reference for the clinical treatment of pulmonary nodules.

Official Title
-----------------
Diagnosis and Management of Incidental Pulmonary Nodules: a Prospective Study

Conditions
-----------------
Lung Nodules

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: LNs patients aged 18 years and older who were previously treated in Guang'anmen hospital. Exclusion Criteria: (1) had the LNs removed; (2) LNs less than or equal to 3 mm in size; (3) had not undergone thorax CT; (4) had failed to complete treatment; (5) had incomplete medical records or was lost to follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in nodule size by CT scan in patients with pulmonary nodules during follow-up. | Changes in nodule size by CT scan in patients with pulmonary nodules during follow-up. | 6 months |
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

Study Overview
=================
Brief Summary
-----------------
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases

Detailed Description
-----------------
Evogliptin 5mg Group: Administration with Evogliptin 5mg and Placebo for 24weeks Pioglitazone 15mg Group: Administration with Pioglitazone 15mg and Placebo for 24weeks

Official Title
-----------------
A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

Conditions
-----------------
Type2 Diabetes, Non-Alcoholic Fatty Liver Disease

Intervention / Treatment
-----------------
* Drug: Evogliptin
* Drug: Pioglitazone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type II diabetes mellitus Subjects who have not been taking any oral hypoglycemic agent within 8 weeks from screening or who have been taking metformin monotherapy at the same dose for more than 8 weeks before screening Subjects with 6.5%≤HbA1c≤9.0% at screening Subjects with 20kg/m2≤BMI≤40kg/m2 at screening Exclusion Criteria: Type I diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus AST > upper normal range*3 Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption Subjects who experienced hypersensitivity reaction against DPP-4 inhibitors, thiazolidinediones Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Evogliptin<br>evogliptin 5mg | Drug: Evogliptin<br>* evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd<br>* Other names: Suganon;|
| Active Comparator: Pioglitazone<br>pioglitazone 15mg | Drug: Pioglitazone<br>* pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd<br>* Other names: Gluconon;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline intrahepatic fat (%) | Changes from baseline intrahepatic fat (%) after treatment with evogliptin or pioglitazone | 24 weeks |
Anti-Obesity Effect of Pediococcus Pentosaceus LP28

Study Overview
=================
Brief Summary
-----------------
This study is designed to evaluate efficacy of Pediococcus pentosaceus LP28 in reducing body fat and body weight in subjects with BMI 25-30 kg/m2.

Official Title
-----------------
A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Effect of Pediococcus Pentosaceus LP28 on Obesity

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Dietary Supplement: Live Pediococcus pentosaceus LP28
* Dietary Supplement: Heat-killed Pediococcus pentosaceus LP28
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI 25-30 kg/m2 Exclusion Criteria: Taking medicines or functional food that may affect body weight or body fat Pregnant or nursing a child Participation in any clinical trial within 90 days of the commencement of the trial Renal or hepatic dysfunction Heart disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br> | Dietary Supplement: Placebo<br> <br> |
| Experimental: Live Pediococcus pentosaceus LP28<br> | Dietary Supplement: Live Pediococcus pentosaceus LP28<br> <br> |
| Experimental: Heat-killed Pediococcus pentosaceus LP28<br> | Dietary Supplement: Heat-killed Pediococcus pentosaceus LP28<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body fat |  | Every 4 weeks (Overall 12 weeks) | 
| BMI | Body weight will be measured every morning. | Every day (Overall 14 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Abdominal circumference |  | Every 4 weeks (Overall 12 weeks) | 
| Serum triglyceride |  | Every 4 weeks (Overall 12 weeks) | 
| Total cholesterol |  | Every 4 weeks (Overall 12 weeks) | 
| LDL cholesterol |  | Every 4 weeks (Overall 12 weeks) | 
| HDL cholesterol |  | Every 4 weeks (Overall 12 weeks) | 
| Fasting blood glucose |  | Every 4 weeks (Overall 12 weeks) | 
| Fasting insulin |  | Weeks 0 and 12 | 
| HOMA-R |  | Weeks 0 and 12 | 
| Adiponectin |  | Weeks 0 and 12 | 
| Leptin |  | Weeks 0 and 12 | 
| Resistin |  | Weeks 0 and 12 |
Blueberry Consumption and Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
Lifestyle strategies that include dietary modification, such as consumption of a plant-based diet, are well recognized in disease prevention and may improve type 2 diabetes. Various components of a plant-based diet may contribute to its beneficial health effects, but there has been keen interest in the possibility that plant polyphenols may have a role. Blueberries are dietary sources of polyphenols, specifically anthocyanins. To date there are few human clinical trials evaluating the beneficial health effects of blueberries in populations with type 2 diabetes. The objective of the study is to determine if freeze-dried blueberries compared to a blueberry placebo will improve cardiometabolic parameters in men with type 2 diabetes.

Official Title
-----------------
Effects of Blueberry Consumption on Cardiometabolic Parameters in Men With Type 2 Diabetes.

Conditions
-----------------
Type2 Diabetes

Intervention / Treatment
-----------------
* Other: Blueberry
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male Ages 45 to 75 years at beginning of study BMI >25 kg/m2 HbA1C > 6.5 and < 9 Medical diagnosis of type 2 diabetes for at least 6 months Exclusion Criteria: Use of insulin Presence of chronic kidney disease (GFR < 45 mL/min), liver cirrhosis, gastrointestinal disease, pancreatic disease, or malabsorption syndromes Weight loss of >10% of body weight over the last 6 months; routine participation in heavy exercise Heavy smokers (>20 cigarettes per day) Unable or unwilling to give informed consent or communicate with study staff Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigators may interfere with study participation or the ability to follow the intervention protocol Allergies to blueberries or blueberry products

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Blueberry<br>22 g freeze-dried blueberries | Other: Blueberry<br>* 22 g freeze-dried whole blueberry powder<br>|
| Placebo Comparator: Placebo<br>22 g placebo | Other: Placebo<br>* 22 g placebo blueberry powder<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Pressure | Systolic blood pressure and diastolic blood pressure. | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemoglobin A1C | Hemoglobin A1C is a surrogate marker of glycemic control over the preceding 2-3 months. | 8 weeks |
QI: Patient Satisfaction With Facial Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate patient satisfaction and quality of life as it relates to skin cancer surgery. This research study involves taking a one-time survey online.

Official Title
-----------------
QI: Patient Satisfaction With Facial Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery

Conditions
-----------------
Skin Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ≥ 18 years of age at the time of surgery. Had a diagnosis of a cutaneous malignancy on the face Cutaneous malignancy includes, but is not limited to basal cell carcinoma, squamous cell carcinoma, and melanoma The face is defined as location in the following areas: forehead, temple, eyebrow, eyelids, cheek, nose, lips, chin, and ears. Able to speak and read English MSK Only Cross Sectional Study: Radiation therapy patients ≥ 18 years of age who have received RT for skin cancer Exclusion Criteria: Unable to speak and read English

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients satisfied with facial appearance | Satisfaction with Facial Appearance Scale, Appearance-related Psychosocial Distress Scale and Adverse Effects Checklist using the FACE-Q Skin Cancer instrument. | 1 year | 
| number of patients satisfied with scar outcome | Appraisal of Scars Scale, Appearance-related Psychosocial Distress Scale and Adverse Effects Checklist using the FACE-Q Skin Cancer instrument. | 1year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality of Life, survey, 18-168
Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Study Overview
=================
Brief Summary
-----------------
This study evaluates the skin toxicities in patients with epidermoid cancer, treated by Radiotherapy in association with Cetuximab.

Official Title
-----------------
Prospective Study About the Association of Radiotherapy and Cetuximab in the Treatment of Epidermoid Cancers, Locally Advanced, of the Head and Neck.

Conditions
-----------------
Epidermoid Head and Neck Cancer

Intervention / Treatment
-----------------
* Drug: Cetuximab
* Radiation: Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Epidermoid head and neck carcinoma locally advanced Indication of Cetuximab and radiotherapy Karnofsky >= 60 Patients participating to another compatible study could be included after consultation with the study director Patients could be beforehand treated for an other ORL cancer The radiotherapy will be delivered for curative aim (minimal dose 66 Gy) Exclusion Criteria: other histology Metastatic disease Recurrent patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patient with epidermoid cancer<br>receiving Cetuximab and radiotherapy | Drug: Cetuximab<br>* First cycle: 400 mg/m2 Next cycles: 250 mg/m2<br>Radiation: Radiotherapy<br>* Curative dose: 66 to 70 Gy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin toxicities | according to NCI-CTCAE version 3.0 | until week 38 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Healthcare and evolution of skin toxicities | Treatment of skin toxicities, according to sponsor advices. | until week 38 | 
| Quality of life | Questionnaire QLQ-C30 | baseline, week 4, month 6 | 
| tumoral efficacy | According to RECIST criteria | 6 months after treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cetuximab, radiotherapy, epidermoid head and neck cancer
Women With Migraine With Aura Neuroimaging Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether a particular form of migraine, migraine with aura, is associated with structural changes in the brain

Official Title
-----------------
Women With Migraine With Aura Neuroimaging (WOMAN) Study: A Population-based Study of Danish Twins

Conditions
-----------------
Migraine With Aura

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female case (migraine with aura), co-twin to case, or control (migraine-free) residency in Denmark no severe neurological (vascular, neurodegenerative or neuroinflammatory) disorders, or other somatic or psychiatric disorders Exclusion Criteria: male residency outside Denmark registered in Civil Registry as not to be contacted by researchers severe neurological (vascular, neurodegenerative or neuroinflammatory) disorders, or other somatic or psychiatric disorders mobile metal parts or other contraindication for MRI weight of 130+ kilograms pregnancy subjects that wished not to be informed about abnormal findings on MRI chronic tension-type headache, medication overuse headache, or cluster headache (diagnosed through physician interview) frequent tension-type headache (control group only, self-reported or diagnosed through physician interview)

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Migraine with aura<br>Participants with migraine with aura (cases), their co-twins, and unrelated migraine-free twins (controls) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of white matter hyperintensities or subclinical ischaemic stroke confirmed by MRI |  | At time of MRI | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of other structural and functional changes in brain |  | At time of MRI | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
migraine with aura, migraine, case-control study, magnetic resonance imaging, brain diseases
Flash Glucose Measurement in Patients on Total Parenteral Nutrition

Study Overview
=================
Brief Summary
-----------------
IV nutrition is a means of providing all the nutritional requirements of people who have severe bowel disease. At least 10% of people on longer term IV nutrition also have diabetes and IV nutrition includes delivering glucose directly to large veins. Unsurprisingly this causes elevated blood glucose levels, particularly in people with diabetes. This can make treatment of hyperglycaemia more challenging. As a result this study aims to use a flash glucose monitoring device, the FreeStyle Libre pro, to investigate what happens to glucose levels in patients receiving IV nutrition. We will look at this trend in 5 patients with diabetes and 5 patients without diabetes receiving IV nutrition.

Official Title
-----------------
What Happens to Frequently Measured Glucose Measures in Patients, Both With and Without Diabetes, Who Are Receiving Total Parenteral Nutrition (TPN).

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: FreeStyle Libre Pro


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants receiving TPN in Leeds with or without diabetes Exclusion Criteria: Patients not receiving TPN Patients who do not speak English Patients who are unable to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients with diabetes on TPN<br>Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN. | Device: FreeStyle Libre Pro<br>* Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.<br>|
| Other: Patients without diabetes on TPN<br>Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN. | Device: FreeStyle Libre Pro<br>* Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hyperglycaemia | Measurements of hyperglycaemia through interstitial glucose levels in patients on a TPN regime | 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Total Parenteral Nutrition